Becton, Dickinson and Company (NYSE:BDX) Posts Earnings Results, Beats Estimates By $0.10 EPS

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10, Zacks reports. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the prior year, the firm posted $3.43 earnings per share. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company updated its FY 2026 guidance to 12.350-12.650 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Closed the life sciences combination with Waters, receiving a $4.0 billion cash distribution and announcing deployment of $2.0 billion to share repurchases (ASR) and $2.0 billion to debt paydown, supporting capital returns and balance-sheet strengthening.
• Q1 revenue was $5.3 billion (up 0.4%) with New BD +2.5% and adjusted EPS $2.91 beating expectations; fiscal 2026 guidance for New BD calls for low single-digit revenue growth, ~25% adjusted operating margin, and adjusted EPS of $12.35–$12.65 (midpoint ? +6%).
• Commercial and innovation momentum across high-growth platforms — double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation; Pyxis Pro launch showing strong competitive conversions and BD has >80 GLP?1 molecules contracted in delivery devices.
• Operational improvements driving margin and cash-flow — BD Excellence delivered ~8% productivity improvement this quarter, manufacturing network reduced to under 50 global sites, and $150M (75%) of a $200M cost-out program already executed.
• Headwinds remain in about 10% of the portfolio — Alaris remediation, lower vaccine demand and China VBP dynamics, plus tariffs (roughly 170 bps hit to gross margin and a material EPS drag) which management says temper near-term results.

Becton, Dickinson and Company Price Performance

BDX opened at $154.52 on Friday. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $44.00 billion, a P/E ratio of 25.21, a PEG ratio of 11.33 and a beta of 0.29. The stock has a 50-day moving average price of $176.64 and a 200-day moving average price of $186.70. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were paid a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 2,713 shares of company stock worth $536,881. 0.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of large investors have recently added to or reduced their stakes in the business. Ausdal Financial Partners Inc. lifted its stake in Becton, Dickinson and Company by 4.0% in the fourth quarter. Ausdal Financial Partners Inc. now owns 2,544 shares of the medical instruments supplier’s stock worth $494,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Bank of Jackson Hole Trust increased its holdings in shares of Becton, Dickinson and Company by 28.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 649 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 145 shares during the period. Prosperity Bancshares Inc bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at about $29,000. Finally, Zions Bancorporation National Association UT boosted its holdings in Becton, Dickinson and Company by 18.3% during the 4th quarter. Zions Bancorporation National Association UT now owns 962 shares of the medical instruments supplier’s stock valued at $187,000 after acquiring an additional 149 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company declared that its board has initiated a share repurchase program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms recently commented on BDX. Jefferies Financial Group reduced their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. JPMorgan Chase & Co. dropped their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Wells Fargo & Company cut their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a report on Tuesday, February 10th. Piper Sandler restated a “neutral” rating and issued a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, Argus dropped their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $191.62.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.